FDA panel backs Gilead’s HIV prevention drug Descovy, except in women
(Reuters) – An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc’s combination drug to reduce the risk of sexually acquired HIV infection in men and transgender…